Project Grant R16DA061946
- This Project Grant award, valued at $282,862 and awarded by the National Science Foundation (NSF) under the Integrative Activities program (CFDA 47.083), supports research at Oklahoma State University (OSU) to investigate the health risks of e-cigarettes and cannabis aerosols, particularly those containing unregulated synthetic cooling agents. The key objectives of this 2-year project are to: (1) quantify exposure and toxicity levels of various vaping aerosol components, (2) assess variability...
- This Project Grant award of $320,000 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop a smoking and vaping cessation treatment based on the drug candidate cytisine. The goal is to explore the feasibility of delivering cytisine through electronic vape administration (EVA) to help stabilize dopamine release and reduce nicotine self-administration in a mouse model of nicotine addiction. Key activities include...
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- The National Institute on Drug Abuse (NIDA) awarded a $639,920 Project Grant on September 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a human laboratory study examining the influence of "natural" cigarillo descriptors on consumer expectancies, subjective effects, smoking behavior, and toxicant exposure. The project, titled "Understanding the Influence of 'Natural' Cigarillo Descriptors on Expectancies, Subjective Effects, Smoking Behavior,...
- Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a Project Grant of $385,638 to The Regents of the University of Colorado (University of Colorado-Denver) under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2025, with a completion date of August 31, 2028. This research award funds a three-year neurobehavioral investigation titled "Cannabinoid Tolerance Across Neurodevelopment: Disruption of Value-Driven Behavior and Prevention Through...
- Federal Grant Award Summary Kaiser Foundation Research Institute received a $681,667 Project Grant award from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning April 1, 2026, with completion targeted for March 31, 2029. This phased R61/R33 award funds the development of a just-in-time adaptive intervention (JITAI) to address concurrent e-cigarette and cannabis use among young adults ages 18–30 in Hawaii. The research leverages...
- Federal Project Grant Award Summary Oregon Health & Science University received a $429,000 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded July 15, 2025, with a completion date of June 30, 2027. The award funds research to develop innovative photopharmacological tools for investigating tetrahydrocannabinol (THC) signaling mechanisms in brain reward circuits. The primary deliverable is the advancement...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Boston Children's Hospital a $489,500 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning June 1, 2025 and concluding May 31, 2027. This research initiative develops and validates remote oral fluid testing procedures to assess cannabis non-use as a key outcome measure in clinical trials targeting younger adults aged 18-30 years with cannabis use disorder (CUD). The project...
- Federal Project Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $317,000 Project Grant to The Research Foundation For The State University of New York (Stony Brook University) on August 7, 2025, under the Oral Diseases and Disorders Research program (CFDA 93.121). This two-year research initiative, concluding August 6, 2027, focuses on chemoprevention strategies for oral squamous cell carcinoma (OSCC) promoted by electronic cigarette exposure. The...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded $248,201 to The Regents of the University of Colorado-Denver on April 15, 2026, for a two-year research project concluding March 31, 2028. The University of Colorado-Denver will conduct a rigorous validation study assessing the performance of cannabis detection devices utilizing two innovative approaches: breath sampling and ocular (pupil...
EMERGING TRENDS IN THE CHEMISTRY OF CANNABIS VAPING AND TOXICANT EMISSIONS - THE PREVALENCE OF CANNABIS VAPING, ESPECIALLY AMONG YOUNG PEOPLE, CONTINUES TO OUTPACE THE UNDERSTANDING OF ITS IMPACT ON PUBLIC HEALTH. THE FREQUENCY OF VAPING CANNABIS AMONG ADOLESCENTS FROM ALL DEMOGRAPHIC GROUPS WAS RECENTLY REPORTED AS 6 TIMES PER MONTH, AND IS RISING FASTER THAN OCCASIONAL USE. CANNABIS CONCENTRATES (CCS), ALSO TERMED EXTRACTS OR OILS, ARE AMONG THE MOST COMMON AND POTENT CANNABIS VAPING FORMULATIONS. CCS ARE TYPICALLY HIGHLY ENRICHED IN CANNABINOIDS SUCH AS THC OR CBD. THC CONCENTRATIONS IN CCS ARE ~50-90% (W/W), WHILE THE THC CONTENT IN CANNABIS PLANT MATERIAL FOR SMOKING IS 10-25%. CURRENTLY, THE NUMBER OF NEW CC FORMULATIONS CONTINUES TO GROW, INCLUDING THE EMERGENCE OF PREVIOUSLY UNKNOWN SEMI-SYNTHETIC CANNABINOIDS, MANY OF WHICH ARE CURRENTLY LEGAL AND READILY AVAILABLE. THE OVERARCHING GOAL OF THIS PROJECT IS TO BRIDGE SIGNIFICANT KNOWLEDGE GAPS INCLUDING UNDERSTANDING HOW SPECIFIC CHEMICAL FORMULATIONS AND VAPORIZER DESIGNS EXACERBATE TOXICANT FORMATION. TO ADDRESS THESE ISSUES, NEW ANALYTICAL METHODOLOGY WILL BE DEVELOPED TO DETERMINE THE ORIGINS OF TOXIC EMISSIONS. A MAIN TOXICANT PRIORITIZED FOR STUDY IN THE APPLICATION IS KETENE, A VIOLENTLY REACTIVE, POTENTIALLY DEADLY POISON GAS WITH HIGH PULMONARY TOXICITY. THE SPECIFIC AIMS OF THE PROPOSED STUDY ARE: 1. DETERMINE CHEMICAL SOURCES OF KETENE EMISSIONS DURING VAPING 2. DETERMINE THE DEVICE-RELATED PARAMETERS THAT MODULATE TOXICANT EMISSIONS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $141.2k | 4/23/25 | ||
| Not listed | $141.2k | 4/30/24 | ||
| Not listed | $141.2k | 4/30/24 |